CorePharma is expanding its development and manufacturing capacities with the incorporation of two new cGMP facilities, showcasing the NJ-based company’s rapid growth in the CDMO sector.

About the New cGMP Facilities

A 20,000 ft² Research and Development facility with Analytical, Development and Pilot Scale cGMP manufacturing capabilities located on its current campus in Middlesex, NJ will enable CorePharma to provide partners with accelerated solutions for their development and clinical trial material needs. It features eight cGMP manufacturing suites tailored for small molecule oral solid dosage products, including containment suites for potent products.
 
Meanwhile, a 35,000 ft² facility located in Edison, NJ will further enhance the company’s manufacturing capabilities, extending them to include liquid products alongside increased capacity for oral solid dosage manufacturing.
 
Both facilities will be operational in Q3 2024.
 
CorePharma anticipates investing up to $10 million in the upcoming year, leading to the creation of an additional 50 job opportunities. With this expansion, CorePharma’s manufacturing footprint extends to more than 150,000 square feet across five facilities, boasting a combined annual manufacturing capacity of 4 billion dosage units across multiple dosage forms.
 
“CorePharma is undergoing a transformational period of growth, and our dedication remains steadfast in investing in both our capabilities and workforce. Our aim is to provide our partners with a comprehensive development-to-commercial CDMO platform for success,” said Arpit Patel, Chief Executive Officer of CorePharma.